Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4482)
All Articles published online
|
Nov 28, 2007 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Bandrés E, Zárate R, Ramirez N, Abajo A, Bitarte N, García-Foncillas J. Pharmacogenomics in colorectal cancer: The first step for individualized-therapy. World J Gastroenterol 2007; 13(44): 5888-5901 [PMID: 17990354 DOI: 10.3748/wjg.v13.i44.5888] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i44/5888.htm |
| Number | Citing Articles |
| 1 |
Eugenia Ch Yiannakopoulou, Debmalya Barh. Omics Approaches in Breast Cancer. 2014; : 499 doi: 10.1007/978-81-322-0843-3_25
|
| 2 |
Martina Blaschke, Jutta Blumberg, Ulrike Wegner, Martin Nischwitz, Giuliano Ramadori, Silke Cameron. Measurements of 5-FU Plasma Concentrations in Patients with Gastrointestinal Cancer: 5-FU Levels Reflect the 5-FU Dose Applied. Journal of Cancer Therapy 2012; 3(01): 28 doi: 10.4236/jct.2012.31004
|
| 3 |
Álvaro Esteban Alfaro Alfaro, Brayan Murillo Castillo, Eugenia Cordero García, Javier Tascón, Ana I. Morales. Colon Cancer Pharmacogenetics: A Narrative Review. Pharmacy 2022; 10(4): 95 doi: 10.3390/pharmacy10040095
|
| 4 |
Scott R. Kelley, Heidi Nelson. Abeloff's Clinical Oncology. 2020; : 1281 doi: 10.1016/B978-0-323-47674-4.00075-X
|
| 5 |
Beatriz Stransky, Pedro Galante. An Omics Perspective on Cancer Research. 2010; : 211 doi: 10.1007/978-90-481-2675-0_12
|
| 6 |
Ana de la Cueva, Ana Ramírez de Molina, Néstor Álvarez-Ayerza, Ma Angeles Ramos, Arancha Cebrián, Teresa Gómez del Pulgar, Juan Carlos Lacal, Irina V. Lebedeva. Combined 5-FU and ChoKα Inhibitors as a New Alternative Therapy of Colorectal Cancer: Evidence in Human Tumor-Derived Cell Lines and Mouse Xenografts. PLoS ONE 2013; 8(6): e64961 doi: 10.1371/journal.pone.0064961
|
| 7 |
E Ch Yiannakopoulou. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. The Pharmacogenomics Journal 2013; 13(2): 105 doi: 10.1038/tpj.2012.42
|
| 8 |
Chih-Ping Hsu, Chih-Cheng Lin, Chiu-Chen Huang, Yi-Hsien Lin, Jyh-Ching Chou, Yu-Ting Tsia, Jhih-Rou Su, Yuan-Chiang Chung. Induction of Apoptosis and Cell Cycle Arrest in Human Colorectal Carcinoma by Litchi Seed Extract. Journal of Biomedicine and Biotechnology 2012; 2012: 1 doi: 10.1155/2012/341479
|
| 9 |
Amirsaeed Sabeti Aghabozorgi, Samaneh Sharif, Reza Jafarzadeh-Esfehani, Saba Vakili, Mohammad Reza Abbaszadegan. Role of miRNA gene variants in the susceptibility and pharmacogenetics of colorectal cancer. Pharmacogenomics 2021; 22(5): 303 doi: 10.2217/pgs-2020-0159
|
| 10 |
Amaia García-Bilbao, Rubén Armañanzas, Ziortza Ispizua, Begoña Calvo, Ana Alonso-Varona, Iñaki Inza, Pedro Larrañaga, Guillermo López-Vivanco, Blanca Suárez-Merino, Mónica Betanzos. Identification of a biomarker panel for colorectal cancer diagnosis. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-43
|
| 11 |
Harshil Shah, Vivek Chavda, Moinuddin M. Soniwala. Bioinformatics Tools for Pharmaceutical Drug Product Development. 2023; : 95 doi: 10.1002/9781119865728.ch6
|
| 12 |
Yogita A. Ghodke-Puranik, Jatinder K. Lamba. Innovative Approaches in Drug Discovery. 2017; : 195 doi: 10.1016/B978-0-12-801814-9.00007-6
|
| 13 |
T. Winder, H.-J. Lenz. Praxis der Viszeralchirurgie Onkologische Chirurgie. 2010; : 187 doi: 10.1007/978-3-642-03808-2_17
|
| 14 |
Young S. Yi, Gil Alterovitz. Pathobiology of Cancer Regimen-Related Toxicities. 2013; : 63 doi: 10.1007/978-1-4614-5438-0_4
|
| 15 |
Ebrahim Eftekhar, Fakhraddin Naghibalhossaini. Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer. Molecular Biology Reports 2014; 41(1): 459 doi: 10.1007/s11033-013-2880-0
|
| 16 |
Hong Ma, Guilin Chen, Mingquan Guo. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer. PROTEOMICS – Clinical Applications 2016; 10(4): 503 doi: 10.1002/prca.201500082
|
| 17 |
Kim M Smits, Arjen HG Cleven, Matty P Weijenberg, Laura AE Hughes, James G Herman, Adriaan P de Bruïne, Manon van Engeland. Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. Pharmacogenomics 2008; 9(12): 1903 doi: 10.2217/14622416.9.12.1903
|
| 18 |
|
| 19 |
Hiroshi Hirata, Yuji Hinoda, Koichi Nakajima, Nobuyuki Kikuno, Yutaka Suehiro, Z. Laura Tabatabai, Nobuhisa Ishii, Rajvir Dahiya. The bcl2 −938CC Genotype Has Poor Prognosis and Lower Survival in Renal Cancer. Journal of Urology 2009; 182(2): 721 doi: 10.1016/j.juro.2009.03.081
|
| 20 |
Bo Yang, Xiande Wang, Dong Dong, Yunqing Pan, Junhua Wu, Jianjian Liu. Existing Drug Repurposing for Glioblastoma to Discover Candidate Drugs
as a New a Approach. Letters in Drug Design & Discovery 2022; 19(1): 31 doi: 10.2174/1570180818666210509141735
|
| 21 |
A. Astier. Apports récents de la pharmacogénomique dans le traitement des cancers colorectaux. Annales Pharmaceutiques Françaises 2010; 68(4): 233 doi: 10.1016/j.pharma.2010.04.001
|